Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

40.99 +0.91 (+2.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
7 Biotech Stocks to Boost Your Portfolio to Peak Health
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
Via InvestorPlace
Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
17 Analysts Have This To Say About Crinetics Pharmaceuticals
 
Via Benzinga
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
18 Analysts Have This To Say About Crinetics Pharmaceuticals
 
Via Benzinga
The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts
 
Via Benzinga
Crinetics Pharmaceuticals: Q4 Earnings Insights
 
Via Benzinga
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy & safety, with plans for FDA submission in 2024. 
Via Benzinga
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. 
Via Benzinga
Crinetics Pharmaceuticals Earnings Preview
 
Via Benzinga
Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals
 
Via Benzinga
8 Analysts Have This to Say About Crinetics Pharmaceuticals
 
Via Benzinga
11 Analysts Have This to Say About Crinetics Pharmaceuticals
 
Via Benzinga
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. 
Via Benzinga
Topics Stocks
Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win
Biotech stock Crinetics Pharmaceuticals rocketed early Tuesday after solid trial results for its oral growth hormone treatment. 
Via Investor's Business Daily
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Why Crinetics Pharmaceuticals Stock Soared This Week
A positive late-stage trial readout fueled a major rally in the drugmaker's shares. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
7 Speculative Stocks Set to Explode Higher
On the search for high-risk, high-reward opportunities? Consider taking a look at these seven speculative stocks. 
Via InvestorPlace
Top 4 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?
Despite good results in phase 3 trials, there are barriers to its drug candidate's success. 
Via The Motley Fool
What's Going On With Crinetics Pharmaceuticals Stock?
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) shares are trading higher Tuesday. 
Via Benzinga
Nasdaq Rises Over 1%; Hostess Brands Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded up 0.29% to 34,676.52 while the NASDAQ rose 1.16% to 13,920.60. The S&P... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study... 
Via Benzinga
Why Shares of Crinetics Pharmaceuticals Are Jumping Monday
The biotech company reported positive phase 3 trial results. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.